Verve Therapeutics Inc (NASDAQ: VERV) is 9.04% higher on its value in year-to-date trading and has touched a low of $4.30 and a high of $14.51 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VERV stock was last observed hovering at around $6.42 in the last trading session, with the day’s loss setting it -0.27%.
Currently trading at $6.15, the stock is -10.29% and -11.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing -4.21% at the moment leaves the stock 3.10% off its SMA200. VERV registered -57.35% loss for a year compared to 6-month gain of 9.63%. The firm has a 50-day simple moving average (SMA 50) of $6.9191 and a 200-day simple moving average (SMA200) of $5.9652.
The stock witnessed a -21.25% loss in the last 1 month and extending the period to 3 months gives it a -14.46%, and is -6.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.15% over the week and 9.70% over the month.
Verve Therapeutics Inc (VERV) has around 274 employees, a market worth around $546.10M and $32.33M in sales. Profit margin for the company is -614.59%. Distance from 52-week low is 42.86% and -57.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.94%).
The EPS is expected to shrink by -12.88% this year
247.0 institutions hold shares in Verve Therapeutics Inc (VERV), with institutional investors hold 94.83% of the company’s shares. The shares outstanding are 88.76M, and float is at 66.18M with Short Float at 22.46%. Institutions hold 90.05% of the Float.
The top institutional shareholder in the company is ALPHABET INC. with over 12.35 million shares valued at $60.26 million. The investor’s holdings represent 14.6618 of the VERV Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.62 million shares valued at $32.31 million to account for 7.9632 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.26 million shares representing 6.3314 and valued at over $25.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 5.3768 of the shares totaling 4.53 million with a market value of $22.1 million.
Verve Therapeutics Inc (VERV) Insider Activity
The most recent transaction is an insider sale by Dorval Allison, the company’s Chief Financial Officer. SEC filings show that Dorval Allison sold 555 shares of the company’s common stock on Dec 02 ’24 at a price of $5.64 per share for a total of $3130.0. Following the sale, the insider now owns 5380.0 shares.
Verve Therapeutics Inc disclosed in a document filed with the SEC on May 14 ’24 that Ashe Andrew D. bought a total of 76,000 shares of the company’s common stock. The trade occurred on May 14 ’24 and was made at $6.26 per share for $0.48 million. Following the transaction, the insider now directly holds 0.34 million shares of the VERV stock.
Still, SEC filings show that on Apr 02 ’24, Nickerson Joan (Chief Administrative Officer) disposed off 1,514 shares at an average price of $8.24 for $12475.0. The insider now directly holds 8,659 shares of Verve Therapeutics Inc (VERV).
